Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Total number of shares and voting rights in Zealand Pharma at March 31, 2023 | |||||||||||
By: GlobeNewswire - 31 Mar 2023 | Back to overview list |
||||||||||
Company announcement – No. 12 / 2023 Total number of shares and voting rights in Zealand Pharma at March 31, 2023 Copenhagen, Denmark, March 31, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. In Company announcement No. 3/2023 from March 9, 2023, and Company announcement No. 8/2023 from March 28, 2023 Zealand announced an increase in share capital relating to exercise of employee warrants. Following these announcements, the table below lists the total number of shares and voting rights in Zealand up to and including March 31, 2023.
In Company announcement No. 10/2023 from March 30, 2023 and Company announcement No. 11/2023 from March 30, 2023, Zealand pharma announced initiation and completion of a directed issue and private placement of 6,578,948 million new ordinary shares. The shares from this directed issue are not yet registered, but expected to be registered and completed by April 4, 2023. # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com. Forward-Looking Statement Contact:
|
|||||||||||
|
|||||||||||
Copyright 2023 GlobeNewswire | Back to overview list |